What Happened?
Boston, MA-based Intarcia Therapeutics Appointed Andrew Young as Chief Scientific Officer
About the Company
We operate with a “No Analog” mindset—continually pushing boundaries, navigating new terrain and unleashing fresh thinking. We are committed to seeking better outcomes which compels us to ask questions that have not been asked before or remain unresolved. We are driven by a desire to create meaningful impact across business, health and society to ease the burden on people living with chronic diseases. Intarcia is a rapidly emerging biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease. Our cross-disciplinary teams include forward-thinking scientists and entrepreneurs collaborating in a fast-paced environment redefining the future of medicine.
About the Person
Andrew Young is Chief Scientific Officer at Intarcia Therapeutics. Previously, Andrew held various senior HR leadership roles in the industry.
Info Source
News
Short Profile